C19061501-F

Denali Therapeutics' DNL343, an eIF2B inhibitor, failed to meet primary and key secondary endpoints in a Phase 2/3 trial for amyotrophic lateral sclerosis (ALS) at 24 weeks.

Sanofi has discontinued a Phase 2 clinical trial of oditrasertib, a Denali-partnered drug, for multiple sclerosis after it failed to meet primary or key secondary endpoints.

The FDA approved Roche's Itovebi, inavolisib, for HR-positive, HER2-negative breast cancer with PIK3CA mutation, to be used with Pfizer’s Ibrance and endocrine therapy.

Sanofi and Denali Therapeutics have discontinued the Phase 2 K2 clinical trial of oditrasertib in multiple sclerosis due to its failure to meet primary and key secondary endpoints.

Sanofi and Denali Therapeutics' SAR443820 (DNL788) did not meet primary or secondary endpoints in a Phase 2 study for amyotrophic lateral sclerosis (ALS).